Sanofi Canada is very pleased to announce that Quebec has extended its listing of DUPIXENT® (dupilumab injection) under the Régie de l'assurance maladie du Québec (RAMQ) to include public reimbursement for Canadians aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The specific criteria for reimbursement are available on the RAMQ website.
DUPIXENT® (dupilumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate-to-severe atopic dermatitis yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Free AI-powered Mobile App for Skin Diseases Coming Soon
April 27, 2021 10:30 ET | Source: Skinopathy Skinopathy North York, Ontario, CANADA
TORONTO, April 27, 2021 (GLOBE NEWSWIRE) Skinopathy Inc., a Canadian medical technology company, will soon release a revolutionary skin disease mobile app that will change how we practice medicine.
Canadians who download the GetSkinHealth app and take pictures of their skin condition will get a pixel-by-pixel Artificial Intelligence (AI) analysis that will look for the presence of skin diseases. The AI will also offer the user the option to schedule an appointment with a skin specialist and hold virtual consultations right through the app.
Fifth indication for DUPIXENT
® in Canada following approvals for moderate-to-severe atopic dermatitis in adults and adolescents, severe chronic rhinosinusitis with nasal polyposis, and severe asthma in adults and adolescents.
For those living with atopic dermatitis, itch has the highest impact on a patient s quality of life.
1
Results from a survey conducted among Canadian children with atopic dermatitis found that 70 per cent experienced loss of sleep and 30 per cent experienced anxiety due to their condition.
2
MISSISSAUGA, ON, Feb. 23, 2021 /CNW/ - Sanofi Canada announced today that Health Canada has approved DUPIXENT
® (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis (AD) in children aged six to 11 years whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.